You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)精神分裂症創新藥獲中國批准上市
阿思達克 01-14 12:09
綠葉製藥(02186.HK)公布,注射用利培酮微球(II)「瑞欣妥」已獲中國藥監局批准上市,是集團第一個由長效緩釋平台開發的獲批上市創新製劑。

瑞欣妥是用於治療精神分裂症的每兩週注射一次的緩釋微球肌肉注射製劑。

除中國市場外,瑞欣妥還在多個海外市場進行開發。目前其在美國處於上市申報階段, 在歐洲完成I期臨床試驗,同時未來計劃在多個新興市場開發並上市。其專利在中國(包括大陸和香港)、美國、歐洲、日本、韓國、俄羅斯、加拿大、澳大利亞均獲得授權,專利期 至2032年。(ic/u) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account